BioCentury
ARTICLE | Clinical News

AP301 regulatory update

January 28, 2013 8:00 AM UTC

Apeptico said FDA and EMA granted Orphan Drug designation to AP301 to treat high altitude pulmonary edema. The product is in Phase IIa testing to treat edematous respiratory failure. AP301 also has Or...